Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,998,482
  • Shares Outstanding, K 536,440
  • Annual Sales, $ 11,077 M
  • Annual Income, $ 480,000 K
  • 36-Month Beta 1.38
  • Price/Sales 1.80
  • Price/Cash Flow 4.89
  • Price/Book 1.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.72 +7.46%
on 10/31/17
39.68 -5.97%
on 10/26/17
-1.61 (-4.14%)
since 10/24/17
3-Month
29.53 +26.35%
on 08/30/17
39.68 -5.97%
on 10/26/17
+7.10 (+23.50%)
since 08/24/17
52-Week
29.39 +26.95%
on 08/15/17
45.87 -18.66%
on 03/01/17
+0.46 (+1.25%)
since 11/23/16

Most Recent Stories

More News
Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference

Mylan N.V. (NASDAQ, TASE: MYL) today announced that its president, Rajiv Malik, will present at the Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference in Boston, Mass., on Thursday, Nov. 30,...

MYL : 37.49 (+0.56%)
Theravance Shares Rise on Approval of Glaxo's COPD Therapy

Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

TBPH : 28.43 (+0.67%)
MYL : 37.49 (+0.56%)
INVA : 13.25 (-1.27%)
GSK : 35.13 (+0.20%)
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.

TBPH : 28.43 (+0.67%)
MYL : 37.49 (+0.56%)
LGND : 133.96 (+0.68%)
ACHN : 3.37 (+0.30%)
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug...

MYL : 37.49 (+0.56%)
TBPH : 28.43 (+0.67%)
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug...

MYL : 37.49 (+0.56%)
TBPH : 28.43 (+0.67%)
Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)

Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Under Israeli law, the delisting of Mylan's...

MYL : 37.49 (+0.56%)
Mylan Launches Generic Clolar® for Injection

Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clofarabine Injection, 20 mg/20 mL (1 mg/mL) Single-Dose Vials, a generic version of Genzyme's Clolar®. Mylan received final approval...

MYL : 37.49 (+0.56%)
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.

MYL : 37.49 (+0.56%)
LGND : 133.96 (+0.68%)
XON : 13.13 (-1.57%)
PBYI : 101.30 (-1.07%)
AGN : 174.06 (-0.44%)
ZTS : 71.22 (+0.21%)
PFE : 35.51 (+0.23%)
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

MYL : 37.49 (+0.56%)
TEVA : 13.66 (+1.34%)
RHHBY : 31.5600 (-0.32%)
GSK : 35.13 (+0.20%)
All Eye On Qualcomm-Broadcom Landmark Deal

All Eye On Qualcomm-Broadcom Landmark Deal

MYL : 37.49 (+0.56%)
CVS : 70.99 (-0.69%)
AAPL : 175.14 (+0.10%)
C : 72.25 (-0.01%)
AVGO : 279.55 (+1.52%)
QCOM : 68.75 (+0.91%)
TWTR : 22.38 (+0.49%)
KORS : 56.67 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 38.11
1st Resistance Point 37.70
Last Price 37.49
1st Support Level 36.93
2nd Support Level 36.57

See More

52-Week High 45.87
Fibonacci 61.8% 39.57
Fibonacci 50% 37.63
Last Price 37.49
Fibonacci 38.2% 35.69
52-Week Low 29.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart